Zasocitinib (TAK-279) by Takeda: status and timeline

Zasocitinib (TAK-279)

Provide a convenient once-daily oral treatment for autoimmune diseases, replacing biologic infusions and offering superior patient outcomes.

DeployStage 4 of 5

FDA Priority Review NDA accepted Sep 2026; PDUFA decision Q1 2027. Phase 3: 70% skin clear.

Updated 27d agoChecked 11 Oct0 updates this week

Milestones

Next · PDUFA decision target (FDA approval decision)

Phase 3 LATITUDE PsO 3001 and 3002 trials completedQ3 2026Complete.
FDA accepts NDA under Priority Review for plaque psoriasis14 Sep 2026Complete.
PDUFA decision target (FDA approval decision)Target Q1 2027Not yet reached.
Phase 2/3 psoriatic arthritis data readoutTarget Q2 2027Not yet reached.
Phase 3 data for Crohn's and UCTarget Q1 2028Not yet reached.

Most important, last 3 months

FDA accepts Zasocitinib (TAK-279) NDA under Priority Review for moderate-to-severe plaque psoriasis; PDUFA decision Q1 202727d ago

Upcoming

Q1 2027PDUFA decision target (FDA approval decision) (next)
Q2 2027Phase 2/3 psoriatic arthritis data readout
Q4 2027Phase 3 data for IBD indications
Q1 2028Phase 3 data for Crohn's and UC

Current obstacles

JAK inhibitor safety profileAll JAK inhibitors carry a black-box warning for infection risk and potential cancer risk; long-term safety surveillance is ongoing.
Competitive landscapeMultiple biologics and small-molecule JAK inhibitors already treat psoriasis; Zasocitinib must differentiate on efficacy, safety, or convenience.

Physics limits

Immune suppression inherent to pathway inhibitionTYK2 is part of the innate immune response; blocking it increases infection risk, requiring careful patient selection and monitoring.
Oral bioavailability challengesSmall-molecule drugs must be designed to pass through the intestinal wall and reach systemic circulation; poor bioavailability can limit efficacy.

How it works

3 parts

TYK2 inhibition

Block TYK2 kinase in JAK pathway

Zasocitinib binds TYK2 and blocks JAK-STAT signaling, which drives immune activation.

Selectivity

TYK2-specific design

Computational chemistry made it selective for TYK2 over other JAK family members.

Effect

Skin inflammation resolves

TYK2 inhibition reduces immune infiltration, clearing psoriatic plaques rapidly in Phase 3.

Spec sheet

Spec	Zasocitinib (TAK-279)
Route of administration	Oral, once-daily^R (reported)
sPGA 0/1 response at week 16 (Phase 3)	~70%^R (reported)
Phase 3 enrollment (3001/3002)	Nearly 3,000^R (reported)
Countries in Phase 3 trials	21 countries^R (reported)

^R reported by the company

Update log

1 update

Mon 14 Sep

Major: FDA accepts Zasocitinib (TAK-279) NDA under Priority Review for moderate-to-severe plaque psoriasis; PDUFA decision Q1 2027PressRegulatory

About Takeda

The team behind Zasocitinib (TAK-279)

Takeda

Zasocitinib, TYK2 inhibitor, AI-designed drug, psoriasis

Takeda is an established, R&D-driven global biopharmaceutical company headquartered in Tokyo with operations in roughly 80 countries. It is advancing Zasocitinib (TAK-279), a computationally designed TYK2 inhibitor for autoimmune and inflammatory diseases.

Established global pharma company; operations in roughly 80 countries; R&D in GI, rare disease, plasma, oncology.
Zasocitinib designed using physics-based computational modeling; Takeda acquired Nimbus Therapeutics, which co-developed the drug.
FDA Priority Review accepted Sep 2026 for plaque psoriasis; ~70% skin clear in Phase 3 at week 16.

takeda.com (opens takeda.com)Company profile →

Founded: 1800226 yrs
Headquarters: Japan
Status: Public
Valuation: public
Works in: BiotechAI drug discovery
Coverage: 1 program · 1 updatelatest 27d agochecked 11 Oct
Partners: Nimbus Therapeutics (opens nimbustx.com)Schrodinger (opens schrodinger.com)

Spec

Zasocitinib (TAK-279)

Route of administration

Oral, once-daily^R (reported)

sPGA 0/1 response at week 16 (Phase 3)

~70%^R (reported)

Phase 3 enrollment (3001/3002)

Nearly 3,000^R (reported)

Countries in Phase 3 trials

21 countries^R (reported)